An AI That Promises to “Solve All Diseases” Is About to Test Its First Human Drugs (gizmodo.com)
from MCasq_qsaCJ_234@lemmy.zip to technology@lemmy.world on 09 Jul 03:18
https://lemmy.zip/post/43521240

#technology

threaded - newest

TheFogan@programming.dev on 09 Jul 03:59 next collapse

I mean I hate AI in general… but to be honest… assuming no one is stupid enough to bypass the trials etc… I’m all for it, 90% of these problems already exist in the existing system, who owns it, can a corporation charge us to death.

The only reasonable fear is, if they come out with more than they can develop trials for, and they lobby to lower standards in trials. Even that honestly is a more acceptable risk in the context of terminal diseases/severe cancers.

pennomi@lemmy.world on 09 Jul 04:00 next collapse

Agreed, drug development is a very good use of AI.

solrize@lemmy.ml on 09 Jul 04:45 collapse

Rfk Jr will use it for drug approvals too! Uh oh.

TheFogan@programming.dev on 09 Jul 06:28 collapse

and it’s still a better system than anyone hired by RFK Jr manually reviewing the file.

Which is kind of the point, idea fully agreed there’s a lot of risks and messed up stuff, but almost all of it, is at worse roughly equal to the already existing problems in our systems… I can’t quite think of any that are made worse.

[deleted] on 09 Jul 08:48 collapse

.

HappySkullsplitter@lemmy.world on 09 Jul 04:07 next collapse

Is this how we all get AIDS?

adespoton@lemmy.ca on 09 Jul 04:19 next collapse

There’s only one way to solve all diseases.

Did they test this on Mars first?

[deleted] on 09 Jul 06:55 next collapse

.

BlameTheAntifa@lemmy.world on 09 Jul 06:57 next collapse

Lovely. Let me pencil “zombie apocalypse” back onto my 2026 BINGO card.

MajinBlayze@lemmy.world on 09 Jul 12:43 collapse

There really needs to be a rhetorical distinction between regular machine learning and something like an llm.

I think people read this (or just the headline) and assume this is just asking grok “what interactions will my new drug flavocane have?” Where these are likely large models built on the mountains of data we have from existing drug trials